Omics-based Clinical Trials Market Opportunities & Forecast 2022-2030

The global omics-based clinical trials market size was valued at USD 25.2 billion in 2020, and is predicted to be worth around USD 50.5 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39105

Growth Factors

Omics has turned out to be the most advanced approach in molecular research. It includes all the field of biological sciences that ends with the suffix – omics. Various disciplines can be classified as omics such as proteomics, genomics, transcriptomics, and metabolomics. The outbreak of coronavirus accelerated the adoption of new approaches, models, and technology in clinical trials, this has positively impacted market growth.

The demand is growing for a pattern shift toward the stratification of patients or even personalized medicine. There are several complex diseases that urgently need a better understanding of their analysis and more effective therapeutic strategies. Currently, omics-based studies make the majority of precision medicine-based data, e.g. DNA sequencing technique is already being used to identify genetic material that enhances specific cancers.

Report Coverage

Report Scope Details
Market Size US$ 50.5 billion by 2030
Growth Rate CAGR of 6.4% From 2022 to 2030
Largest Market North America
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Phase, Study design, Indication
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Parexel International Corporation; Pharmaceutical Product Development (PPD); Charles River Laboratory, ICON plc, SGS SA; Eli Lilly and Company; Pfizer Inc.; Covance Inc.; Novo Nordisk; Rebus Bio

By Phase Analysis

The phase II segment dominated the market for omics-based clinical trials and accounted for the largest revenue share of 37.8% in 2021. The segment is expected to witness a CAGR of 7.1% over the forecast period.

Phase II clinical trials had the highest number of projects in 2020 and this trend is expected to grow further owing to increasing investments in R&D by industry and non-industry sponsors.

By Study Design Analysis

The interventional studies segment dominated the market for omics-based clinical trials and accounted for the largest revenue share of 78.3% in 2021.

The segment is expected to exhibit a CAGR of 7.1% over the forecast period owing to the increasing number of interventional designs of clinical trials. Interventional studies are categorized based on the intervention that is to be studied which includes drug or biologic, surgical procedure, behavioral, and devices.

The expanded access studies segment is anticipated to witness a lucrative CAGR of 8.6% during the forecast period. Interventional study designs are known to provide the most reliable data in epidemiological research in genomics or any other omics-based studies.

By Indication Analysis

The oncology segment dominated the market for omics-based clinical trials and accounted for the largest revenue share of 46.7% in 2021. The segment is expected to witness a CAGR of 7.6% during the forecast period.

The worldwide cancer cases are projected to grow by 50% and worldwide cancer deaths are expected to rise by 60% till 2030 which indicates growing potential for the omics-based clinical trial in this segment.

The research on cardiology is ideally positioned to address the epidemic of noninfectious causes of death, as well as advance the understanding of human health and disease, through the development and implementation of precision medicine.

By Regional Analysis

North America dominated the market for omics-based clinical trials and held the largest revenue share of 43.6% in 2021. This can be attributed to the huge R&D investments, the presence of global players, and their efforts to come up with newer patents.

Asia Pacific is the fastest growing market as many developed nations are investing in Asia-Pacific regions. Besides, the recruitment for clinical trials is increasing in Asia as compared to North America, and Europe. This is due to the large patient pool and low trial cost.

Key Players

  • Parexel International Corporation
  • Pharmaceutical Product Development (PPD)
  • Charles River Laboratory
  • ICON plc
  • SGS SA
  • Eli Lilly and Company
  • Pfizer Inc.
  • Covance Inc.
  • Novo Nordisk
  • Rebus Bio

Market Segmentation

  • By Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • By Study Design
    • Interventional Studies
    • Observational Studies
    • Expanded Access Studies
  • By Indication
    • Oncology
    • Cardiology
    • Respiratory Diseases
    • Skin Diseases
    • CNS Diseases
    • Immunology
    • Genetic Diseases (includes the rare diseases)
    • Others (includes ophthalmic, ear diseases, etc)
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39105

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Omics-Based Clinical Trials Market, By Phase

7.1.  Omics-Based Clinical Trials Market, by Phase, 2021-2030

7.1.1.    Phase I

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Phase II

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Phase III

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Phase IV

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Omics-Based Clinical Trials Market, By Study Design

8.1.  Omics-Based Clinical Trials Market, by Study Design, 2021-2030

8.1.1.    Interventional Studies

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Observational Studies

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Expanded Access Studies

8.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Omics-Based Clinical Trials Market, By Indication

9.1.  Omics-Based Clinical Trials Market, by Indication, 2021-2030

9.1.1.    Oncology

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Cardiology

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Respiratory Diseases

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Skin Diseases

9.1.4.1.        Market Revenue and Forecast (2017-2030)

9.1.5.    CNS Diseases

9.1.5.1.        Market Revenue and Forecast (2017-2030)

9.1.6.    Immunology

9.1.6.1.        Market Revenue and Forecast (2017-2030)

9.1.7.    Genetic Diseases (includes the rare diseases)

9.1.7.1.        Market Revenue and Forecast (2017-2030)

9.1.8.    Others (includes ophthalmic, ear diseases, etc)

9.1.8.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Omics-Based Clinical Trials Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.1.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.1.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.2.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.2.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.3.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.3.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.4.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.4.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.5.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.5.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

Chapter 11.  Company Profiles

11.1.              Parexel International Corporation

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Pharmaceutical Product Development (PPD)

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Charles River Laboratory

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              ICON plc

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              SGS SA

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Eli Lilly and Company

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Pfizer Inc.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Covance Inc.

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Novo Nordisk

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Rebus Bio

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39105

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com